Program
libevitug
Also written as “HH-003(20mg/kg)”, “HH-003(10mg/kg)” and “Libevitug 20 mg/kg”.
Its studies are mostly in Hepatitis D · Hepatitis B, Chronic, led by Huahui Health.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Huahui Health | 61 open or running | phase 3since Mar 24, 2026 | Sep 11, 2022 | Sep 12, 2028phase 3 · NCT07499544 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 11, 2022First study: phase 1 study in Chronic HBV InfectionFirst studyNCT05542979 · 68 enrolled · China
- Dec 30, 2022Phase 2 study in Hepatitis B, ChronicNCT05674448 · 9 enrolled · China
- Feb 9, 2023Phase 2 study in Chronic HBV InfectionNCT05734807 · 74 enrolled · China
- Apr 20, 2023Phase 2 study in Hepatitis B, ChronicNCT05839639 · 73 enrolled · China
- May 7, 2023Phase 2 study in Chronic Hepatitis Delta Virus InfectionNCT05861674 · 101 enrolled · China, Pakistan
- Mar 24, 2026Phase 3 study in Hepatitis DPhase 3 reachedNCT07499544 · 160 planned · United States, China, Pakistan
Ahead
- Sep 12, 2028Primary completion: phase 3 study in Hepatitis DNCT07499544
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07499544Hepatitis D · United States, China, Pakistan | 3 | Recruiting | Sep 12, 2028 | 160 |
| NCT05861674Chronic Hepatitis Delta Virus Infection · China, Pakistan | 2 | Completed | Jul 18, 2024 | 101 |
| NCT05839639Hepatitis B, Chronic · China | 2 | Completed | Dec 5, 2022 | 73 |
| NCT05734807Chronic HBV Infection · China | 2 | Completed | Apr 17, 2024 | 74 |
| NCT05674448Hepatitis B, Chronic · China | 2 | Terminated | Jul 25, 2022 | 9 |
| NCT05542979Chronic HBV Infection · China | 1 | Completed | Mar 15, 2022 | 68 |
How it is read
Names in the registry
- “HH-003(20mg/kg)”, 1 entry
- “HH-003(10mg/kg)”, 1 entry
- “Libevitug 20 mg/kg”, 1 entry
- “Libevitug 10 mg/kg”, 1 entry
- “HH-003 and NrtIs”, 1 entry
Codes read as this program: HH003.
Conditions, from the studies’ own filings
- Hepatitis D, 2 studies
- Hepatitis B, Chronic, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.